529 related articles for article (PubMed ID: 30259383)
1. Mechanisms of Resistance to Immune Checkpoint Blockade.
Liu D; Jenkins RW; Sullivan RJ
Am J Clin Dermatol; 2019 Feb; 20(1):41-54. PubMed ID: 30259383
[TBL] [Abstract][Full Text] [Related]
2. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
Moujaess E; Haddad FG; Eid R; Kourie HR
Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
4. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.
Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM
J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757
[TBL] [Abstract][Full Text] [Related]
5. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
[TBL] [Abstract][Full Text] [Related]
6. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C
Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885
[TBL] [Abstract][Full Text] [Related]
7. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Anagnostou V; Smith KN; Forde PM; Niknafs N; Bhattacharya R; White J; Zhang T; Adleff V; Phallen J; Wali N; Hruban C; Guthrie VB; Rodgers K; Naidoo J; Kang H; Sharfman W; Georgiades C; Verde F; Illei P; Li QK; Gabrielson E; Brock MV; Zahnow CA; Baylin SB; Scharpf RB; Brahmer JR; Karchin R; Pardoll DM; Velculescu VE
Cancer Discov; 2017 Mar; 7(3):264-276. PubMed ID: 28031159
[TBL] [Abstract][Full Text] [Related]
8. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P
Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555
[TBL] [Abstract][Full Text] [Related]
9. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
Warner AB; Postow MA
Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
Tintelnot J; Stein A
World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
[TBL] [Abstract][Full Text] [Related]
11. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer.
Li TJ; Wang WQ; Yu XJ; Liu L
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188384. PubMed ID: 32531324
[TBL] [Abstract][Full Text] [Related]
12. Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.
Rozeman EA; Dekker TJA; Haanen JBAG; Blank CU
Am J Clin Dermatol; 2018 Jun; 19(3):303-317. PubMed ID: 29164492
[TBL] [Abstract][Full Text] [Related]
13. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients.
Subrahmanyam PB; Dong Z; Gusenleitner D; Giobbie-Hurder A; Severgnini M; Zhou J; Manos M; Eastman LM; Maecker HT; Hodi FS
J Immunother Cancer; 2018 Mar; 6(1):18. PubMed ID: 29510697
[TBL] [Abstract][Full Text] [Related]
14. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
18. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
Rivera Vargas T; Apetoh L
Front Immunol; 2019; 10():1181. PubMed ID: 31191545
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
20. Curing tumor-bearing mice by shifting a Th2 to a Th1 anti-tumor response.
Hellstrom KE; Dai M; Hellstrom I
Hum Antibodies; 2017; 25(3-4):147-153. PubMed ID: 28085017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
